Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial-Reference-Cited by-同舟云学术

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

Published:2017-07-04 Issue:2 Volume:32 Page:383-390
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Goldschmidt H,Lokhorst H M,Mai E K,van der Holt B,Blau I W,Zweegman S,Weisel K C,Vellenga E,Pfreundschuh M,Kersten M J,Scheid C,Croockewit S,Raymakers R,Hose D,Potamianou A,Jauch A,Hillengass J,Stevens-Kroef M,Raab M S,Broijl A,Lindemann H W,Bos G M J,Brossart P,van Marwijk Kooy M,Ypma P,Duehrsen U,Schaafsma R M,Bertsch U,Hielscher T^ORCID,Jarari Le,Salwender H J,Sonneveld P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2017211.pdf

Reference47 articles.

1. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.

2. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142–152.

3. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29–37.

4. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366: 1759–1769.

5. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571.

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma;Blood Cancer Journal;2024-09-11

2. Meta-analysis of effectiveness and safety of proteasome inhibitor-dependent maintenance treatment for multiple myeloma a systematic review;Heliyon;2024-08

3. Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation;JCO Precision Oncology;2024-07

4. Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-06-28

5. Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma—Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries;International Journal of Molecular Sciences;2024-06-11